Kimball Electronics (KE) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
10 Nov, 2026Company profile and platform
Global EMS and medical CDMO provider serving complex, highly regulated industries; FY26 revenue was $1.4B, with 5,500+ employees.
Integrated capabilities span design and development, prototyping, NPI or transfer of work, manufacturing, testing, and aftermarket support.
Manufacturing footprint spans 11 locations across North America, Europe, and Asia, with an in-region operating focus.
EMS offerings include PCB and system assembly, capital equipment assembly, prototyping, and supply chain management; medical CDMO includes molding, cleanroom assembly, cold chain, and complex devices.
End markets
FY26 net sales mix: Automotive 46%, Medical 29%, and Industrial 25%.
Automotive strengths include electronic power steering and braking; vehicle electrification and rising electronic content support demand.
Medical portfolio covers respiratory care, diagnostics, surgical systems, drug delivery, patient monitoring, and imaging, with a focus on Class II and Class III devices.
Industrial markets include factory automation, off-highway equipment, clean energy, public safety, climate control, and smart energy management.
Strategic priorities and Helvoet
Portfolio actions include divesting Automation, Test & Measurement, closing the Tampa facility, elevating medical CDMO, and guiding for organic growth in FY27.
Helvoet acquisition closed July 1; its medical CDMO operations in Tilburg and Pune bring 585+ employees, precision molding, microfluidics, cleanroom assembly, and tooling capabilities.
Helvoet adds an EU and India footprint for global medtech programs and offers potential EMS pull-through; the acquisition is expected to be accretive to earnings.
Growth strategy prioritizes medical CDMO, drug delivery, scalable capabilities, and selective M&A; potential areas include cardiology, orthopedics, minimally invasive surgery, and surgical instruments.
A phased rebranding to Kimball Solutions began at selected locations in July 2026, with completion targeted for July 2027; a shareholder vote and proposed ticker change to KMBL were upcoming.
Latest events from Kimball Electronics
- Sales rose 7%, led by Medical and Helvoet, while reported earnings fell.KE
Q1 2027 - Key votes include director elections, auditor ratification, and a proposed company name change.KE
Proxy filing - Shareholders to vote on director elections, auditor, executive pay, and rebranding to Kimball Solutions.KE
Proxy filing - Shareholders to vote on directors, auditor, executive pay, and a rebrand amid strong performance.KE
Proxy filing - Q4 growth and margin gains set up a 7–9% FY27 outlook, driven by medical and Helvoet.KE
Q4 2026 - Medical segment growth and new facility drive raised outlook and margin expansion plans.KE
2026 KeyBanc Capital Markets Healthcare Forum - Acquisition expands global medical CMO platform, boosting growth and earnings by 2027.KE
M&A announcement - Profitable growth expected as medical and automotive markets drive margin expansion and investment.KE
Company presentation - Q1 FY2025 sales fell 15% as restructuring and asset sales improved cash flow and reduced debt.KE
Q1 2025